Similar efficacy and safety between lenvatinib versus atezolizumab plus bevacizumab as the first‐line treatment for unresectable hepatocellular carcinoma

Similar efficacy and safety between lenvatinib versus atezolizumab plus bevacizumab as the first‐line treatment for unresectable hepatocellular carcinoma

Abstract Background Lenvatinib and atezolizumab plus bevacizumab(A + B) have been used for unresectable hepatocellular carcinoma (HCC) as first‐line therapy. Real‐world studies comparison of efficacy and safety in these two regimens are limited, we therefore conduct this study to investigate these i...

Full description

Bibliographic Details
Main Authors: Chung‐Wei Su, Wei Teng, Po‐Ting Lin, Wen‐Juei Jeng, Kuei‐An Chen, Yi‐Chung Hsieh, Wei‐Ting Chen, Ming‐Mo Ho, Chia‐Hsun Hsieh, Ching‐Ting Wang, Pei‐Mei Chai, Chen‐Chun Lin, Chun‐Yen Lin, Shi‐Ming Lin
Format: Article
Language:English
Published: Wiley 2023-03-01
Series:Cancer Medicine
Subjects:
adverse event
atezolizumab plus bevacizumab
hepatocellular carcinoma
lenvatinib
survival
Online Access:https://doi.org/10.1002/cam4.5506

Internet

https://doi.org/10.1002/cam4.5506

Similar Items